American Journal of Psychiatry

Article	Citations
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	427
Broadening the Parameters of Clinical High Risk for Psychosis	349
2024 Annual Meeting: Presidential Address	188
Evaluating Associations Between Cannabis and Heroin Use	178
Treating Pathologies of the Will	171
Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia	151
Mental Health Disparities Research: An Introduction to New Directions	133
Highlights From the Residents’ Journal: December 2021	129
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	117
COVID-19 and Stress-Related Disorders	115
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	106
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	104
Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?	103
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	101
On the Genetic and Environmental Relationship Between Suicide Attempt and Death by Suicide	97
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	90
Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology	89
Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	87
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	86
Intentional Drug Overdose Deaths in the United States	82
Depression, Inflammation, and Postpartum Psychosis	81
20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis	81
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	79
The First Large GWAS Meta-Analysis for Postpartum Depression	78
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	77

An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	77
2024 Annual Meeting: CEO and Medical Director’s Address	76
Highlights From the Residents’ Journal: September 2021	75
Correcting Overestimations in Self-Harm Visit Data	74
APA Council Reports	71
Highlights From the Residents’ Journal: September 2024	68
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	67
Correction to Poirot et al.	67
Corrigendum to Morley et al.	67
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	64
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	64
Suicide and the Menstrual Cycle	62
Coordinate Network Mapping: An Emerging Approach for Morphometric Meta-Analysis	57
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	57
New Insights Into Psychotic Disorders	57
Whole Brain White Matter Tract Deviation and Idiosyncrasy From Normative Development in Autism and ADHD and Unaffected Siblings Link With Dimensions of Psychopathology and Cognition	56
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression	56
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	53
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	52
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	51
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial	50
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	50
Early Adversity and Development: Parsing Heterogeneity and Identifying Pathways of Risk and Resilience	50
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	50
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings	49
Familial Risk of Postpartum Psychosis	49
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	49
Sexual Identity Continuity and Change in a U.S. National Probability Sample of Sexual Minority Adults: Associations With Mental Health and Problematic Substance Use	48
Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes	48
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	47
Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry	46
Rebecca W. Brendel, M.D., J.D., 149th President, 2022–2023	45
Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities	45
Neurobiological Models of Alcohol Use Disorder in Humans	44
The Safety of Pimavanserin for Parkinson’s Disease and Efforts to Reduce Antipsychotics for People With Dementia	43
The Neglected Role of Psychotherapy for Treatment-Resistant Depression	42
Comment on “Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank”	41
Shared and Specific Neural Correlates of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Meta-Analysis of 243 Task-Based Functional MRI Studies	40
Alcohol and the Etiology of Depression	40
Sustained Efficacy of Stanford Neuromodulation Therapy (SNT) in Open-Label Repeated Treatment	39
Predictive Value of Acute Neuroplastic Response to rTMS in Treatment Outcome in Depression: A Concurrent TMS-fMRI Trial	38
Risk of Incident Psychosis and Mania With Prescription Amphetamines	38
Aberrant Developmental Patterns of Gamma-Band Response and Long-Range Communication Disruption in Youths With 22q11.2 Deletion Syndrome	38
Reduction in Trauma-Related Symptoms After Anesthetic-Induced Intra-Operative Dreaming	37
Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank	37
Suicide in Black Females	37
2021 Articles of Import and Impact	37
Evaluating the Machine Learning Literature: A Primer and User’s Guide for Psychiatrists	36
Synaptic Variability and Cortical Gamma Oscillation Power in Schizophrenia	36
Slowly Working Toward More Treatments for Depression in Bipolar II Disorder	36

Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression	35
Modification of Heritability for Educational Attainment and Fluid Intelligence by Socioeconomic Deprivation in the UK Biobank	35
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary	34
Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain	33
Cigarette Smoking and Heavy Alcohol Drinking: The Challenges and Opportunities for Combination Treatments	32
Predicting Acute Changes in Suicidal Ideation and Planning: A Longitudinal Study of Symptom Mediators and the Role of the Menstrual Cycle in Female Psychiatric Outpatients With Suicidality	32
Double-Blind, Sham-Controlled Randomized Trial Testing the Efficacy of fMRI Neurofeedback on Clinical and Cognitive Measures in Children With ADHD	32
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder	32
Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment	32
What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis	31
Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial	31
Neuromodulation Strategies for the Treatment of Depression	31
Neural Correlates of Stress and Alcohol Cue-Induced Alcohol Craving and of Future Heavy Drinking: Evidence of Sex Differences	31
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders	31
Correction to Baum et al.	30
Can Smartphone-Based Support Apps Add Value to the Treatment of Opioid Use Disorder?	30
The Association of Childhood Maltreatment and Mental Health Problems: Partly Causal and Partly Due to Other Factors	30
Psilocybin: From Psychiatric Pariah to Perceived Panacea	30
Changing the Face of Schizophrenia	30
Keeping Track and Providing Tools for Future Crisis Management: Suicide Attempt and Self-Harm Presentations at Emergency Departments	29
Drug Cues Trigger Corticolimbic Hyperreactivity in Heroin Users	29
Racial and Ethnic Biases and Psychiatric Misdiagnoses: Toward More Equitable Diagnosis and Treatment	29
Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries	28
Evaluating the Evidence for Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	28
Toward Precision Noninvasive Brain Stimulation	28
Psychiatric Diagnoses in Parents and Psychiatric, Behavioral, and Psychosocial Outcomes in Their Offspring: A Swedish Population-Based Register Study	28
Setting the Record Straight on Long-Term Use, Dose Escalation, and Potential Misuse of Prescription Benzodiazepines	28
Harnessing the Power of Population Cohorts to Study the Relationship Between Endocrine-Metabolic Disorders and Depression	27
Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD	27
Differences in Social Determinants of Health Underlie Racial/Ethnic Disparities in Psychological Health and Well-Being: Study of 11,143 Older Adults	27
Innovative Directions to Advance Mental Health Disparities Research	26
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability	26
The Amygdala and Depression: A Sober Reconsideration	26
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review	25
Interindividual Differences in Cortical Thickness and Their Genomic Underpinnings in Autism Spectrum Disorder	25
Structural Racism as a Proximal Cause for Race-Related Differences in Psychiatric Disorders	25
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial	25
Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary	25
Auditory Steady-State Responses Probe GABA-Related Oscillatory Cortical Circuits and Their Relation to Neurodevelopmental Mental Disorders	25
Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?	24
2024 Articles of Import and Impact	24
Correction	24
Highlights From the Residents’ Journal: December 2024	24
Ketamine After Two Antidepressants?	24
Understanding the Effects of Combined Lisdexamfetamine and Cognitive Behavior Therapy for Adults With Binge Eating Disorder	24
Guilt by Association: Inflammation and Shared Genetic Risk Between Stress-Related and Immune Disorders	24
Current and Future Approaches to Pediatric Anxiety Disorder Treatment	23
Recommendations for the Usage of Ketamine and Esketamine	23
Drugs and Addiction Science: NIDA Celebrates 50 Years of Research and Looks to the Future	22
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy	22
Functional Connectivity Mapping for rTMS Target Selection in Depression	22
Time Course of Relapse Following Acute Treatment for Anorexia Nervosa	22
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg	22
Cannabis Use and the Endocannabinoid System: A Clinical Perspective	22
Longitudinal Trajectory of the Link Between Ventral Striatum and Depression in Adolescence	22
Progress and Challenges in GxE Research on Depression	22
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial	21
Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression	21
Associations Between General and Specific Mental Health Conditions in Young Adulthood and Cardiometabolic Complications in Middle Adulthood: A 40-Year Longitudinal Familial Coaggregation Study of 672,	21
Converging Evidence for Frontopolar Cortex as a Target for Neuromodulation in Addiction Treatment	21
Neural Substrates of Vulnerability to Anxiety in Response to Stressful Life Events: A COVID-19 Study	21
Technology and Mental Health: State of the Art for Assessment and Treatment	21
Behavior as Physiology: How Dynamical-Systems Theory Could Advance Psychiatry	21
Perinatal Mental Health: Advances and Opportunities	20
Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction	20
Functional Connectome Prediction of Anxiety Related to the COVID-19 Pandemic	20
Vaccines as Immunotherapies for Substance Use Disorders	20
Late-Life Depression, Antidepressant Treatment, and Cognition: The Short Haul and the Long Haul	20
Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population	20
Reports to the Membership	20
Can Two 90-Minute Workshops Reduce Risk of Substance Use Disorder for Vulnerable Seventh Graders? Results and Scalability From the Co-Venture Trial	20
Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donors’ Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia	20
Auditory Oddball Responses Across the Schizophrenia-Bipolar Spectrum and Their Relationship to Cognitive and Clinical Features	20
Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?	19
Antidepressants and Bipolar Disorder: The Plot Thickens	19
Anticholinergic Medication Burden–Associated Cognitive Impairment in Schizophrenia	19
Psychotropic Drug–Related Weight Gain and Its Treatment	19
An Insula-Enriched Regulator of Retinoic Acid Marks a New Intersection in the Neural Circuitry of Mouse Social Behavior	18
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research	18
Neglect of Adverse Effects in Treatment Guidelines for Depression	18

Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort	18
Putting Genetics to Work in the Psychiatric Clinic	18
Polygenic Risk Scores and Genetics in Psychiatry	18
Highlights From the Residents’ Journal: September 2023	18
Clozapine’s High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies—How Do We Get There?	17
Comment on “Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids”: Response to Rubinow et al.	17
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment	17
Focusing on Substance Use Disorders, Opioids, and Craving	17
Effects of County-Level Opioid Dispensing Rates on Individual-Level Patterns of Prescription Opioid and Heroin Consumption: Evidence From National U.S. Data	17
Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes	17
Intermittent Theta Burst Stimulation With Adjunctive D-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial	16
Neuropsychiatric Symptoms of Subacute and Chronic Long COVID	16
Increased Inflammation in Depression: A Little in All, or a Lot in a Few?	16
Understanding the Value and Limitations of MRI Neuroimaging in Psychiatry	16
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder	16
The Risk of Overdose With Concomitant Use of Z-Drugs and Prescription Opioids: A Population-Based Cohort Study	16
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia	16
Affective Disorders, Pharmacogenomics, and Psychiatric Illness-Related Cardiometabolic Problems	15
New Insights Into Major Depression and the Treatment of Bipolar Depression	15
Beyond the Landmarks: Where to Next With Biomarkers of Autism?	15
The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders	15
Intergenerational Effects of the Fast Track Intervention on Next-Generation Child Outcomes: A Preregistered Randomized Clinical Trial	15
Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study	15
MORE Is Less Pain and Less Opioid Misuse: A Mindful Remedy	15
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?	15
Reports to the Membership	15
Disclosure of Editors’ Financial Relationships	15